Enzalutamide has 11 known drug interactions based on U.S. FDA drug labeling data. Of these, 4 are contraindicated combinations that should be avoided entirely. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Doravirine, Doravirine, Lamivudine, And Tenofovir Disoproxil Fumarate, Fostemsavir Tromethamine. Patients taking Enzalutamide should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 11
- Contraindicated
- 4
- Major
- 3
- Moderate
- 3
Contraindicated (4)
- Enzalutamide + Doravirine— Androgen Receptors enzalutamide ↓ doravirine Co-administration is contraindicated with enzalutamide.
- Enzalutamide + Doravirine, Lamivudine, And Tenofovir Disoproxil Fumarate— Androgen Receptors enzalutamide ↓ doravirine Co-administration is contraindicated with enzalutamide.
- Enzalutamide + Fostemsavir Tromethamine— Concomitant Drug Class: Drug Name Effect on Concentration of Temsavir and/or Concomitant Drug Clinical Comment Androgen …
- Enzalutamide + Nirmatrelvir And Ritonavir— Anticancer drugs apalutamide, enzalutamide ↓ nirmatrelvir/ritonavir Co-administration contraindicated due to potential l…
Major (3)
- Enzalutamide + Macimorelin Acetate— Strong CYP3A4 inducer may reduce plasma macimorelin concentrations and lead to false positive test results. Discontinue …
- Enzalutamide + Palbociclib— Avoid concomitant use of strong CYP3A inducers (e.g., phenytoin, rifampin, carbamazepine, enzalutamide, and St John's Wo…
- Enzalutamide + Rydapt— Strong CYP3A4 inducer that decreases midostaurin concentrations and may reduce efficacy. Avoid coadministration.
Moderate (3)
- Enzalutamide + Digoxin— XTANDI can interfere with certain digoxin immunoassays, resulting in falsely elevated digoxin plasma concentration resul…
- Enzalutamide + Gemfibrozil— Gemfibrozil is a strong CYP2C8 inhibitor that may increase enzalutamide exposure; dosing reduction may be required.
- Enzalutamide + Rifampin— Strong CYP3A4 inducer that decreases plasma concentrations of enzalutamide and N-desmethyl enzalutamide, may decrease ef…